(Q47889050)

6 February 2018

title

Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? (English)

1 reference

6 February 2018

0 references

1 reference

2

Miller LH

1 reference

6 February 2018

Stowers AW

1

1 reference

6 February 2018

publication date

1 September 2001

1 reference

6 February 2018

published in

Trends in Parasitology

1 reference

6 February 2018

volume

17

1 reference

6 February 2018

issue

9

1 reference

6 February 2018

page(s)

415-419

1 reference

6 February 2018

Vaccines against the blood stages of falciparum malaria.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Research toward vaccines against malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Child mortality and malaria transmission intensity in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Induction of protective immunity against experimental infection with malaria using synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Efficiency of human Plasmodium falciparum malaria vaccine candidates in Aotus lemurinus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Efficacy trial of malaria vaccine SPf66 in Gambian infants

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Humoral immune responses during a malaria vaccine trial in Tanzanian infants

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Vaccines for preventing cholera

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902011-6

7 January 2021

10.1016/S1471-4922(01)02011-6

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018